Filing Details
- Accession Number:
- 0000899243-19-025695
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-10-17 16:55:46
- Reporting Period:
- 2019-10-16
- Accepted Time:
- 2019-10-17 16:55:46
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1706431 | Vir Biotechnology Inc. | VIR | Biological Products, (No Disgnostic Substances) (2836) | 812730369 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1731509 | Ltd (Uk) Advisers Investment Sb | 69 Grosvenor Street London X0 W1K 3JW | No | No | Yes | No | |
1755143 | L.p. M1) (Aiv Fund Vision Softbank | 251 Little Falls Drive Wilmington DE 19808 | No | No | Yes | No | |
1782338 | Ltd (Cayman) Endurance Svf | C/O Walkers Corp Ltd Cayman Corp Centre 27 Hospital Road Georgetown, Grand Cayman E9 KY1-9008 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2019-10-16 | 21,666,666 | $0.00 | 21,666,666 | No | 4 | C | Indirect | See footnote |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2019-10-16 | 950,000 | $20.00 | 22,616,666 | No | 4 | P | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See footnote |
No | 4 | P | Indirect | See footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series A-1 Convertible Preferred Stock | Disposition | 2019-10-16 | 15,555,555 | $0.00 | 15,555,555 | $0.00 |
Common Stock | Series B Convertible Preferred Stock | Disposition | 2019-10-16 | 6,111,111 | $0.00 | 6,111,111 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- The Series A-1 Convertible Preferred Stock and the Series B Convertible Preferred Stock each converted into Vir Biotechnology, Inc. common stock on a one-to-one basis and had no expiration date.
- Represents securities held directly by SVF Endurance (Cayman) Limited. SVF Endurance (Cayman) Limited is a wholly-owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments.
- (continued from footnote 2) SBIA UK is wholly owned by SoftBank Group Corp. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission that any reporting person is the beneficial owner of such shares for purposes of the Securities Exchange Act of 1934 or for any other purpose.